The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 12, 2022

Filed:

Jul. 19, 2019
Applicants:

Immunolight, Llc, Detroit, MI (US);

Duke University, Durham, NC (US);

Inventors:

Tuan Vo-Dinh, Chapel Hill, NC (US);

Jonathan P. Scaffidi, Durham, NC (US);

Venkata Gopal Reddy Chada, Durham, NC (US);

Benoit Lauly, Durham, NC (US);

Yan Zhang, Durham, NC (US);

Molly K. Gregas, Durham, NC (US);

Ian Nicholas Stanton, Durham, NC (US);

Joshua T. Stecher, Durham, NC (US);

Michael J. Therien, Durham, NC (US);

Frederic A. Bourke, Jr., Aspen, CO (US);

Harold Walder, Oak Island, NC (US);

Zak Fathi, Raleigh, NC (US);

Jennifer A. Ayres, Raleigh, NC (US);

Zhenyuan Zhang, Durham, NC (US);

Joseph H. Simmons, Tucson, AZ (US);

Stephen John Norton, Cary, NC (US);

Assignees:

Immunolight, LLC, Detroit, MI (US);

Duke University, Durham, NC (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61N 5/06 (2006.01); A61K 49/00 (2006.01); A61N 1/40 (2006.01); A61N 5/02 (2006.01); A61B 5/00 (2006.01); A61B 5/055 (2006.01); A61B 6/00 (2006.01); A61K 41/00 (2020.01); A61M 5/00 (2006.01); A61L 2/00 (2006.01); A61L 2/08 (2006.01); A61N 5/067 (2006.01); A61N 5/10 (2006.01);
U.S. Cl.
CPC ...
A61N 5/062 (2013.01); A61B 5/0059 (2013.01); A61B 5/0071 (2013.01); A61B 5/055 (2013.01); A61B 5/4848 (2013.01); A61B 6/481 (2013.01); A61K 41/0042 (2013.01); A61K 41/0052 (2013.01); A61K 41/0061 (2013.01); A61K 49/0039 (2013.01); A61L 2/0047 (2013.01); A61M 5/007 (2013.01); A61N 1/406 (2013.01); A61N 5/02 (2013.01); A61N 5/0601 (2013.01); A61L 2/08 (2013.01); A61L 2202/21 (2013.01); A61L 2202/22 (2013.01); A61N 5/067 (2021.08); A61N 5/0618 (2013.01); A61N 5/0622 (2013.01); A61N 5/0624 (2013.01); A61N 5/10 (2013.01); A61N 2005/063 (2013.01); A61N 2005/0656 (2013.01); A61N 2005/0659 (2013.01); A61N 2005/0662 (2013.01); A61N 2005/1098 (2013.01);
Abstract

Products, compositions, systems, and methods for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The methods may be performed in situ in a non-invasive manner by placing a nanoparticle having a metallic shell on at least a fraction of a surface in a vicinity of a target structure in a subject and applying an initiation energy to a subject thus producing an effect on or change to the target structure directly or via a modulation agent. The nanoparticle is configured, upon exposure to a first wavelength λ, to generate a second wavelength λof radiation having a higher energy than the first wavelength λ. The methods may further be performed by application of an initiation energy to a subject in situ to activate a pharmaceutical agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.


Find Patent Forward Citations

Loading…